HOMER3

HOMER3 is a multidomain scaffold protein that couples signaling receptors to downstream effectors through its EVH1 ligand-binding and coiled-coil polymerization domains, organizing complexes across neuronal, immune, and cancer contexts (PMID:18480293, PMID:25589726). In Purkinje cells it links mGluR1α and the IP3R suppressor domain via the EVH1 domain, with the IP3R engaging a PPKKF motif and an F40 conformational switch on the EVH1 surface (PMID:24901889); CaMKII phosphorylation of HOMER3 lowers its affinity for mGluR1α, driving dissociation from the postsynaptic density into the cytosol and reshaping mGluR1α-induced Ca2+ signaling (PMID:18480293). Beyond scaffolding the receptor, long HOMER3 isoforms bridge mGluR1α to the 26S proteasome through the S8 ATPase subunit, promoting its ubiquitination and degradation (PMID:22486777). HOMER3 also acts downstream of mTORC1 in Purkinje cells, and restoring its expression in SCA1 model neurons attenuates cellular dysfunction and motor deficits (PMID:26748090). In immune cells, HOMER3 is recruited to the immunological synapse by association with a ubiquitin-like domain of IKKβ to regulate actin dynamics independently of NF-κB activation (PMID:20693425), translocates to the nucleus to suppress SRE-driven transcription via C/EBPβ binding (PMID:14645007), and serves as a Gαi2-binding scaffold in neutrophils that organizes PIP3 and actin polarity downstream of GPCR activation while leaving Rac and PI3K kinetics intact (PMID:25739453). HOMER3 binds the cytoplasmic tail of APP in a Ca2+-regulated manner to inhibit APP/BACE1 maturation and reduce Aβ secretion (PMID:18387811, PMID:24792907, PMID:25589726), and it interacts with NFATc1 and calcineurin to restrain RANKL-induced osteoclast differentiation (PMID:31319381). In cancer, HOMER3 scaffolds oncogenic complexes—c-Src/β-Catenin in triple-negative breast cancer (PMID:33407765), SRC/YAP1 in prostate cancer (PMID:40849586), and CAMKK1/TRPV6 and CAMKK1/TUBB3 in oral squamous cell carcinoma (PMID:41326663)—promoting tumor signaling, metastasis, and chemoresistance.

1. 2003 Medium

   Established that HOMER3 functions beyond neurons by linking TCR engagement to transcriptional control, answering whether this scaffold acts in immune signaling.

   Evidence Overexpression/knockdown, SRE luciferase reporter, co-IP with C/EBPβ, and confocal localization in Jurkat T cells

   PMID:14645007

   Open questions at the time

   • No structural definition of the EVH1–C/EBPβ interface
   • Nuclear translocation mechanism not defined
2. 2005 Low

   Raised the possibility that HOMER3 binds PAX6, addressing whether it engages transcription factors implicated in eye development.

   Evidence Yeast two-hybrid screen with disease-associated PAX6 C-terminal mutants

   PMID:16098226

   Open questions at the time

   • Yeast two-hybrid only, no biochemical or in vivo validation
   • Functional consequence of the interaction untested
3. 2008 High

   Defined how synaptic activity dynamically regulates HOMER3 scaffolding, showing that CaMKII phosphorylation toggles its receptor coupling state.

   Evidence In vitro kinase assay, phospho-specific fractionation, Purkinje cell depolarization with CaMKII inhibitor, binding kinetics, and Ca2+ signaling readout

   PMID:18480293

   Open questions at the time

   • Specific phosphosites controlling mGluR1α affinity not fully mapped
   • In vivo behavioral consequence not addressed
4. 2008 Medium

   Identified a HOMER3 role in APP processing, answering whether the scaffold modulates amyloidogenic pathways.

   Evidence Co-IP, cell-surface APP assay, and Aβ ELISA in transfected cells

   PMID:18387811

   Open questions at the time

   • No in vivo validation of Aβ effect
   • Mechanism of maturation inhibition not resolved
5. 2010 Medium

   Resolved how HOMER3 reaches the immunological synapse and distinguished its actin role from NF-κB signaling.

   Evidence Co-IP with IKKβ ubiquitin-like domain, confocal colocalization, and Homer3-KO T cells with intact NF-κB

   PMID:20693425

   Open questions at the time

   • Molecular link from IKKβ recruitment to actin remodeling unknown
   • Single lab
6. 2012 Medium

   Showed HOMER3 not only scaffolds mGluR1α but targets it for degradation, revealing a receptor turnover function.

   Evidence Reciprocal co-IP with proteasomal S8 ATPase, siRNA knockdown, and ubiquitination/surface mGluR1α assays

   PMID:22486777

   Open questions at the time

   • E3 ligase mediating ubiquitination not identified
   • Isoform specificity mechanism not detailed
7. 2014 Medium

   Provided structural and Ca2+-regulatory detail of HOMER3 EVH1 ligand binding, defining the IP3R-binding surface and the Ca2+ sensitivity of the APP complex.

   Evidence NMR chemical shift mapping with EVH1 mutants; co-IP under Ca2+ perturbations in HEK293 and neuroblastoma cells

   PMID:24792907 PMID:24901889

   Open questions at the time

   • EVH1 NMR study lacks cellular functional validation
   • Ca2+ sensor coupling APP complex to influx not identified
8. 2015 High

   Established HOMER3 as a Gαi2-binding scaffold positioning it downstream of GPCRs in neutrophil polarity, and mapped APP-binding determinants.

   Evidence Affinity chromatography and RNAi epistasis in HL-60 cells with PIP3/F-actin imaging; domain-deletion and phospho-mutant co-IP for APP

   PMID:25589726 PMID:25739453

   Open questions at the time

   • How HOMER3 organizes WAVE2 persistence mechanistically unknown
   • Gαi2 binding interface not structurally defined
9. 2016 High

   Placed HOMER3 as a functional effector downstream of mTORC1 whose restoration rescues neurodegenerative phenotype, linking its expression level to disease.

   Evidence SCA1 Purkinje cell proteomics, rapamycin treatment, mTORC1 conditional KO, and AAV Homer-3 re-expression with motor behavior

   PMID:26748090

   Open questions at the time

   • Transcriptional/translational mechanism of mTORC1 control of Homer-3 unclear
   • Downstream targets mediating rescue not defined
10. 2019 High

    Demonstrated HOMER3 restrains osteoclastogenesis through calcineurin/NFATc1, revealing a brake on NFAT nuclear translocation.

    Evidence Homer2/3 DKO BMMs, RANKL osteoclast assay, NFATc1 imaging, co-IP, and cyclosporin A rescue with bone density measurement

    PMID:31319381

    Open questions at the time

    • Relative contributions of Homer2 vs Homer3 not separated
    • Direct calcineurin-binding interface undefined
11. 2025 Medium

    Extended HOMER3 scaffolding into oncogenic signaling, showing it assembles SRC/YAP1 and CAMKK1/TRPV6/TUBB3 complexes driving immunosuppression and chemoresistance.

    Evidence Co-IP, YAP1 phosphorylation and fractionation, calcium influx and pathway westerns, microtubule and docetaxel assays, and in vivo tumor models

    PMID:40849586 PMID:41326663

    Open questions at the time

    • Domain requirements for these cancer complexes not mapped
    • Whether scaffolding is constitutive or regulated unclear

• It remains unknown what unifying biochemical principle governs HOMER3 partner selection across its neuronal, immune, and oncogenic complexes, and how phosphorylation and Ca2+ jointly set its scaffolding state in each tissue.
• No integrated structural model of HOMER3 complex assembly across contexts
• Isoform-specific roles incompletely defined
• Physiological selection between competing partners unresolved